Emerging research suggest this peptide, a dual agonist targeting both incretin and GIP , appears to offer a promising step forward for body management . Preliminary human trials have demonstrated considerable reductions in body mass , possibly surpassing current body composition treatments. Despite this, more assessment is necessary to thoroughly u